Scientists test Next-Gen COVID booster aiming for longer protection
NCT ID NCT07183709
Summary
This early-stage study is testing the safety and immune response of a new COVID-19 booster vaccine called PepGNP-COVID19. The vaccine uses tiny gold particles to deliver parts of the virus, aiming to train the body's T-cells for a strong and lasting defense, especially in the lungs. The trial will enroll 60 healthy adults, aged 18-64, who have already received their primary COVID-19 vaccinations and at least one booster.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cincinnati Children's Hospital Medical Center Vaccine Research Center
Cincinnati, Ohio, 45229, United States
-
George Washington University Medical Faculty Associates
Washington D.C., District of Columbia, 20037-3201, United States
-
University of Alabama at Birmingham School of Medicine - Infectious Disease
Birmingham, Alabama, 35222, United States
Conditions
Explore the condition pages connected to this study.